Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination with either Bortezomib or Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma

Next Previous
X
Search
Trial Profile

An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination with either Bortezomib or Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Melphalan flufenamide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ANCHOR
  • Sponsors Oncopeptides

    • Most Recent Events

    • 15 Jun 2023 Results (n=23; data cutoff date: as of 9 Feb 2022) reporting final data presented at the 28th Congress of the European Haematology Association
    • 03 Sep 2022 This trial has been completed in Czechia (End date: 02 Feb 22), according to European Clinical Trials Registry record.
    • 16 Feb 2022 Status changed from active, no longer recruiting to discontinued, according an Oncopeptides media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top